Telehealth company Hims & Hers has added Grail’s blood cancer test Galleri to its offerings as the medtech has now sent off ...

Byonyks has developed expertise in manufacturing APD Cyclers and Tubing sets, maintains a technical support team, and is now ...

Galleri is a multi-cancer early detection (MCED) or 'liquid biopsy' test that Grail says can spot signs of up to 50 different ...

Clair, a Stanford-founded startup, is developing a wearable hormone tracking device to give women noninvasive insights into ...

Let’s be clear: 7-OH is not a public health crisis. According to the Food and Drug Administration’s (FDA) own Adverse Event Reporting System (FAERS), and shown in the Marwood Report, there have been ...

Half of the planned 200 ALS patients have joined Medicinova’s expanded access program evaluating the experimental drug MN-166.

At a starting cost of just $49 per month, the new pills are the cheapest GLP-1 option yet. But experts say compounded drugs ...

Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced three significant U.S. milestones that expand access, choice ...

Manufacturers and pharmacies are buckling under demand for estradiol patches used to treat symptoms of menopause and ...

PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 23, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX) (“Medicus” or the ...

In today’s Pharma Pulse, the FDA launches its "PreCheck" pilot to speed up domestic factory approvals, while new SELECT trial data shows that semaglutide significantly slashes hospital admission rates ...

The approval of oral GLP-1 therapies marks a notable evolution in obesity management, expanding therapeutic choice beyond injectable options. Although this development could improve uptake among ...